GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: SMT-026738
Compound class:
Synthetic organic
Comment: SMT-738 is from a novel class of antibacterial compounds that have activity against carbapenem-resistant Enterobacteriaceae (CREs) [1]. The structure is claimed in patent WO2022233886A1 that was filed by Discuva Ltd. (acquired by Summit Therapeutics in 2017) [2]. Functionally, it inhibits LolCDE [1], a complex that is essential for the transport of lipoproteins from the inner membrane to the outer membrane of Gram-negative bacteria.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Breidenstein EBM, Khan N, Duffy T, Coward C, Avis T, Abdulle O, Li C-M, Mason CS. (2024)
SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae. Antimicrob Agents Chemother, 68 (1): e0069523. [PMID:38084954] |
|
2. Khan MN, Breidenstein EB, Bye A. (2022)
Antibacterial compound. Patent number: WO2022233886A1. Assignee: Discuva Ltd. Priority date: 03/05/2022. Publication date: 10/11/2022. |